Literature DB >> 24091326

Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse.

Joseph C Cheng, Aiping Bai, Thomas H Beckham, S Tucker Marrison, Caroline L Yount, Katherine Young, Ping Lu, Anne M Bartlett, Bill X Wu, Barry J Keane, Kent E Armeson, David T Marshall, Thomas E Keane, Michael T Smith, E Ellen Jones, Richard R Drake, Alicja Bielawska, James S Norris, Xiang Liu.   

Abstract

Escape of prostate cancer (PCa) cells from ionizing radiation-induced (IR-induced) killing leads to disease progression and cancer relapse. The influence of sphingolipids, such as ceramide and its metabolite sphingosine 1-phosphate, on signal transduction pathways under cell stress is important to survival adaptation responses. In this study, we demonstrate that ceramide-deacylating enzyme acid ceramidase (AC) was preferentially upregulated in irradiated PCa cells. Radiation-induced AC gene transactivation by activator protein 1 (AP-1) binding on the proximal promoter was sensitive to inhibition of de novo ceramide biosynthesis, as demonstrated by promoter reporter and ChIP-qPCR analyses. Our data indicate that a protective feedback mechanism mitigates the apoptotic effect of IR-induced ceramide generation. We found that deregulation of c-Jun induced marked radiosensitization in vivo and in vitro, which was rescued by ectopic AC overexpression. AC overexpression in PCa clonogens that survived a fractionated 80-Gy IR course was associated with increased radioresistance and proliferation, suggesting a role for AC in radiotherapy failure and relapse. Immunohistochemical analysis of human PCa tissues revealed higher levels of AC after radiotherapy failure than those in therapy-naive PCa, prostatic intraepithelial neoplasia, or benign tissues. Addition of an AC inhibitor to an animal model of xenograft irradiation produced radiosensitization and prevention of relapse. These data indicate that AC is a potentially tractable target for adjuvant radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24091326      PMCID: PMC3784522          DOI: 10.1172/JCI64791

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  110 in total

1.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer.

Authors:  Deborah A Kuban; Susan L Tucker; Lei Dong; George Starkschall; Eugene H Huang; M Rex Cheung; Andrew K Lee; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-31       Impact factor: 7.038

2.  Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer.

Authors:  Xiang Liu; S Elojeimy; A M El-Zawahry; D H Holman; A Bielawska; J Bielawski; S Rubinchik; G-W Guo; J-Y Dong; T Keane; Y A Hannun; M Tavassoli; James S Norris
Journal:  Mol Ther       Date:  2006-08-01       Impact factor: 11.454

Review 3.  Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report.

Authors:  J S Norris; A Bielawska; T Day; A El-Zawahri; S ElOjeimy; Y Hannun; D Holman; M Hyer; C Landon; S Lowe; J Y Dong; J McKillop; K Norris; L Obeid; S Rubinchik; M Tavassoli; S Tomlinson; C Voelkel-Johnson; X Liu
Journal:  Cancer Gene Ther       Date:  2006-06-09       Impact factor: 5.987

Review 4.  Principles of bioactive lipid signalling: lessons from sphingolipids.

Authors:  Yusuf A Hannun; Lina M Obeid
Journal:  Nat Rev Mol Cell Biol       Date:  2008-02       Impact factor: 94.444

5.  The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy.

Authors:  Antonio F Saad; William D Meacham; Aiping Bai; Viviane Anelli; Saeed Elojeimy; Ayman E M Mahdy; Lorianne S Turner; Joe Cheng; Alicja Bielawska; Jacek Bielawski; Thomas E Keane; Lina M Obeid; Yusuf A Hannun; James S Norris; Xiang Liu
Journal:  Cancer Biol Ther       Date:  2007-06-23       Impact factor: 4.742

6.  Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy.

Authors:  Saeed Elojeimy; Xiang Liu; John C McKillop; Ahmed M El-Zawahry; David H Holman; Jonathan Y Cheng; William D Meacham; Ayman Em Mahdy; Antonio F Saad; Lorianne S Turner; Joseph Cheng; Terrence A Day; Jian-Yun Dong; Alicja Bielawska; Yusuf A Hannun; James Scott Norris
Journal:  Mol Ther       Date:  2007-04-10       Impact factor: 11.454

7.  Novel analogs of D-e-MAPP and B13. Part 1: synthesis and evaluation as potential anticancer agents.

Authors:  Zdzislaw M Szulc; Nalini Mayroo; AiPing Bai; Jacek Bielawski; Xiang Liu; James S Norris; Yusuf A Hannun; Alicja Bielawska
Journal:  Bioorg Med Chem       Date:  2007-08-24       Impact factor: 3.641

8.  Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.

Authors:  Patrick A Kupelian; Twyla R Willoughby; Chandana A Reddy; Eric A Klein; Arul Mahadevan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-06-04       Impact factor: 7.038

9.  Identification of aberrant forms of alkaline sphingomyelinase (NPP7) associated with human liver tumorigenesis.

Authors:  Y Cheng; J Wu; E Hertervig; S Lindgren; D Duan; A Nilsson; R-D Duan
Journal:  Br J Cancer       Date:  2007-10-09       Impact factor: 7.640

10.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.

Authors:  David P Dearnaley; Matthew R Sydes; John D Graham; Edwin G Aird; David Bottomley; Richard A Cowan; Robert A Huddart; Chakiath C Jose; John Hl Matthews; Jeremy Millar; A Rollo Moore; Rachel C Morgan; J Martin Russell; Christopher D Scrase; Richard J Stephens; Isabel Syndikus; Mahesh K B Parmar
Journal:  Lancet Oncol       Date:  2007-06       Impact factor: 41.316

View more
  62 in total

1.  Expression of Ceramide Synthase 6 Transcriptionally Activates Acid Ceramidase in a c-Jun N-terminal Kinase (JNK)-dependent Manner.

Authors:  Tejas S Tirodkar; Ping Lu; Aiping Bai; Matthew J Scheffel; Salih Gencer; Elizabeth Garrett-Mayer; Alicja Bielawska; Besim Ogretmen; Christina Voelkel-Johnson
Journal:  J Biol Chem       Date:  2015-04-03       Impact factor: 5.157

Review 2.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Authors:  Jean-Philip Truman; Mónica García-Barros; Lina M Obeid; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-12-30

3.  Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells.

Authors:  Li-Pin Kao; Samy A F Morad; Traci S Davis; Matthew R MacDougall; Miki Kassai; Noha Abdelmageed; Todd E Fox; Mark Kester; Thomas P Loughran; Jose' L Abad; Gemma Fabrias; Su-Fern Tan; David J Feith; David F Claxton; Sarah Spiegel; Kelsey H Fisher-Wellman; Myles C Cabot
Journal:  J Lipid Res       Date:  2019-07-30       Impact factor: 5.922

4.  Targeting (cellular) lysosomal acid ceramidase by B13: design, synthesis and evaluation of novel DMG-B13 ester prodrugs.

Authors:  Aiping Bai; Zdzislaw M Szulc; Jacek Bielawski; Jason S Pierce; Barbara Rembiesa; Silva Terzieva; Cungui Mao; Ruijuan Xu; Bill Wu; Christopher J Clarke; Benjamin Newcomb; Xiang Liu; James Norris; Yusuf A Hannun; Alicja Bielawska
Journal:  Bioorg Med Chem       Date:  2014-10-22       Impact factor: 3.641

Review 5.  Sphingolipids in the DNA damage response.

Authors:  Brittany Carroll; Jane Catalina Donaldson; Lina Obeid
Journal:  Adv Biol Regul       Date:  2014-11-18

6.  IL-17 induces radiation resistance of B lymphoma cells by suppressing p53 expression and thereby inhibiting irradiation-triggered apoptosis.

Authors:  Qingshan Li; Xin Xu; Weijie Zhong; Qinghua Du; Bizhen Yu; Huabao Xiong
Journal:  Cell Mol Immunol       Date:  2014-12-29       Impact factor: 11.530

Review 7.  Ceramidases, roles in sphingolipid metabolism and in health and disease.

Authors:  Nicolas Coant; Wataru Sakamoto; Cungui Mao; Yusuf A Hannun
Journal:  Adv Biol Regul       Date:  2016-10-11

Review 8.  Ceramide induced mitophagy and tumor suppression.

Authors:  Mohammed Dany; Besim Ogretmen
Journal:  Biochim Biophys Acta       Date:  2015-01-26

9.  Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1/S1PR4/matriptase.

Authors:  Cheng-Fan Lee; Andrew Dang; Elizabeth Hernandez; Rey-Chen Pong; Benjamin Chen; Rajni Sonavane; Ganesh Raj; Payal Kapur; Hsin-Ying Lin; Shang-Ru Wu; Chun-Jung Ko; U-Ging Lo; Hsin-Yu Lee; Jer-Tsong Hsieh; Ming-Shyue Lee
Journal:  Oncogene       Date:  2019-05-31       Impact factor: 9.867

Review 10.  The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.

Authors:  Su-Fern Tan; Jennifer M Pearson; David J Feith; Thomas P Loughran
Journal:  Expert Opin Ther Targets       Date:  2017-05-02       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.